Table 1 Patient demographics

Age, years

63

 ± 11

65

 ± 13

62

 ± 10

0.42^c

BMI, (kg/m²)

27.4

[24.6–31.4]

27.8

[24.6–36.6]

26.9

[24.6–30.3]

0.37^d

Smoking, n (%)

3

(11.5)

26

1

(8.3)

12

2

(14.3)

14

0.56^b

Comorbidities, n (%)

 Diabetes mellitus II

12

(35.3)

2

(14.3)

10

(50.0)

0.035^b

  Metformin

7

(21.9)

32

1

(7.1)

6

(30.0)

18

0.087^b

  Insulin

2

(6.3)

32

0

(0.0)

2

(10.0)

18

0.31^b

  SGLT2-inhibitors

2

(6.3)

32

0

(0.0)

0

(0.0)

18

–

  SU-derivatives

2

(6.3)

32

0

(0.0)

2

(10.0)

18

0.31^b

 Hypertension

15

(44.1)

5

(35.7)

10

(50.0)

0.41^a

  Beta blocker

8

(25.0)

32

5

(35.7)

3

(15.0)

18

0.21^b

  Diuretics

8

(25.0)

32

3

(21.4)

5

(25.0)

18

0.50^b

  Calcium channel blockers

3

(9.4)

32

0

(0.0)

3

(15.0)

18

0.17^b

  ACE-inhibitors

7

(21.9)

32

3

(21.4)

4

(20.0)

18

0.65^b

  Angiotensin II receptor blockers

4

(12.5)

32

3

(21.4)

1

(5.0)

18

0.21^b

 Chronic kidney disease

3

(8.8)

2

(14.3)

1

(5.0)

0.37^b

Complications, n (%)

 AKI

11

(32.4)

0

(0.0)

11

(55.0)

0.001^b

 ARDS

20

(58.8)

0

(0.0)

20

(100.0)

 < 0.001^a

Mechanical ventilation, days

14

[10–21]

–

14

[10–21]

Days between symptom onset and admission sample

9

 ± 5

9

 ± 6

9

 ± 4

0.89^c

Ward stay, days

–

8

[6–13]

7*

[5–16]

–

ICU stay, days

–

–

16

[12–23]

–

Total hospital stay, days

15

[10–24]

8

[6–13]

20

[14–29]

 < 0.001^d

90-day mortality,

n (%)

11

(32.4)

0

(0.0)

11

(55.0)

0.001^b